Medical Oncology Division, Igea SpA, 80013 Naples, Italy.
Division of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale-IRCCS di Napoli, 80131 Naples, Italy.
Curr Oncol. 2024 Jan 10;31(1):403-424. doi: 10.3390/curroncol31010027.
The aim of this informative review was to investigate the application of radiomics in cancer imaging and to summarize the results of recent studies to support oncological imaging with particular attention to breast cancer, rectal cancer and primitive and secondary liver cancer. This review also aims to provide the main findings, challenges and limitations of the current methodologies. Clinical studies published in the last four years (2019-2022) were included in this review. Among the 19 studies analyzed, none assessed the differences between scanners and vendor-dependent characteristics, collected images of individuals at additional points in time, performed calibration statistics, represented a prospective study performed and registered in a study database, conducted a cost-effectiveness analysis, reported on the cost-effectiveness of the clinical application, or performed multivariable analysis with also non-radiomics features. Seven studies reached a high radiomic quality score (RQS), and seventeen earned additional points by using validation steps considering two datasets from two distinct institutes and open science and data domains (radiomics features calculated on a set of representative ROIs are open source). The potential of radiomics is increasingly establishing itself, even if there are still several aspects to be evaluated before the passage of radiomics into routine clinical practice. There are several challenges, including the need for standardization across all stages of the workflow and the potential for cross-site validation using real-world heterogeneous datasets. Moreover, multiple centers and prospective radiomics studies with more samples that add inter-scanner differences and vendor-dependent characteristics will be needed in the future, as well as the collecting of images of individuals at additional time points, the reporting of calibration statistics and the performing of prospective studies registered in a study database.
本次综述旨在研究放射组学在癌症成像中的应用,并总结最近的研究结果,以支持癌症影像学,特别关注乳腺癌、直肠癌以及原发性和继发性肝癌。本次综述还旨在提供当前方法学的主要发现、挑战和局限性。本综述纳入了过去四年(2019-2022 年)发表的临床研究。在分析的 19 项研究中,没有一项研究评估了扫描仪之间的差异和与供应商相关的特征、在额外时间点采集个体的图像、进行校准统计、代表在研究数据库中进行的前瞻性研究、进行成本效益分析、报告临床应用的成本效益,或进行多变量分析且纳入非放射组学特征。有七项研究达到了较高的放射组学质量评分(RQS),有十七项研究通过考虑来自两个不同机构的两个数据集以及开放科学和数据领域的验证步骤获得了额外分数(基于一组有代表性 ROI 计算的放射组学特征是开源的)。放射组学的潜力正在不断得到确立,即使在将放射组学纳入常规临床实践之前,仍有几个方面需要评估。存在几个挑战,包括需要在工作流程的所有阶段进行标准化,以及在使用真实世界异质数据集进行跨站点验证的潜力。此外,未来还需要多个中心和前瞻性放射组学研究,纳入更多样本以增加扫描仪之间的差异和与供应商相关的特征,以及在额外时间点采集个体的图像、报告校准统计以及进行在研究数据库中注册的前瞻性研究。